menu
    • menu
    [{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"KRAS","graph1":"Oncology","graph2":"Undisclosed","graph3":"Taiho Pharmaceutical","amount2":2.5499999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":2.5499999999999998,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Taiho Pharmaceutical \/ Merck"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"AB154","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Taiho Pharmaceutical","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"HM06","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Lung Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"LTI-01","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"SHP2","graph1":"Oncology","graph2":"Discovery","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Taiho Pharmaceutical \/ Merck"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fosnetupitant Chloride","moa":"NK1 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Domvanalimab","moa":"TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fosnetupitant Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Pharmaceutical","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"Inhalation","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CLN-081","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vepafestinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"CLN-081","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Taiho Pharmaceutical","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.40999999999999998,"dosageForm":"Tablet","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tegafur","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Phost'in Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PhOx430","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Araris Biotech","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Quemliclustat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Nuntius Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Taiho Pharmaceutical \/ Taiho Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Taiho Pharmaceutical

    Menu

    Taiho Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Nuntius Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nuntius Partners with Taiho to Develop Next-Gen mRNA Therapies with Cell-Specific Tech

                            Details : Taiho will use Nuntius’ proprietary cell-specific delivery technology, peptide dendrimer- and lipid-based nanocarriers to develop novel mRNA cancer immunotherapies.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 15, 2024

                            Lead Product(s) : mRNA-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Nuntius Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat,Zimberelimab,Etrumadenant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Arcus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Taiho Exercises License Option for Quemliclustat in Japan and Asia

                            Details : Under the license agreement, Taiho will further support the development & commercialization of AB680 (quemliclustat) & will operationalize the PRISM-1 study in Japan as part of its mission.

                            Brand Name : AB680

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 08, 2024

                            Lead Product(s) : Quemliclustat,Zimberelimab,Etrumadenant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Arcus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Recipient : Araris Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs U...

                            Details : Under the collaboration, Araris will use its proprietary linker-conjugation platform to generate next-generation novel ADCs against undisclosed targets provided by Taiho.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 08, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Recipient : Araris Biotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PhOx430

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Phost\'in Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Taiho Pharmaceutical and Phost’in Therapeutics Announce an Option and License Agreement on the First-in-Clas...

                            Details : Under the agreement, Taiho will obtain option rights for PhOx430, a first-in-class small molecule targeting GnT-V and additional undisclosed compounds and to exclusively develop and commercialize the compounds in Japan and certain other territories in As...

                            Brand Name : PhOx430

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 25, 2023

                            Lead Product(s) : PhOx430

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Phost\'in Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tegafur,Gimeracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Taiho Pharmaceutical Obtains Additional Indication of "Postoperative Adjuvant Chemotherapy for Hormone Recepto...

                            Details : TS-1 is a combination of three pharmacological compounds: tegafur, an antimetabolite agent that, after absorption by the gastrointestinal tract, is converted into the anticancer agent fluorouracil (5-FU); gimeracil (5-chloro-2, 4-dihydroxypyridine, or CD...

                            Brand Name : TS-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 24, 2022

                            Lead Product(s) : Tegafur,Gimeracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLN-081

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Cullinan Therapeutics

                            Deal Size : $405.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop a...

                            Details : Taiho has also completed its acquisition of Cullinan Oncology’s subsidiary, Cullinan Pearl Corp. (Cullinan Pearl) which has worldwide rights outside of Japan* to CLN-081/TAS6417.

                            Brand Name : TAS6417

                            Molecule Type : Small molecule

                            Upfront Cash : $275.0 million

                            June 23, 2022

                            Lead Product(s) : CLN-081

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Cullinan Therapeutics

                            Deal Size : $405.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vepafestinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Data on Helsinn's Oncology Pipeline Presented at American Society of Clinical Oncology (ASCO) Annual Meeti...

                            Details : Vepafestinib (TAS0953/HM06) is an investigational, potent, orally administered, highly selective RET inhibitor, is pharmacologically distinct, exhibits a distinct binding mode to RET, and has shown evidence of enhanced brain penetrability characteristics...

                            Brand Name : TAS0953

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 02, 2022

                            Lead Product(s) : Vepafestinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Helsinn Advanced Synthesis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLN-081

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Cullinan Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with ...

                            Details : TAS6417 (CLN-081), is designed as a next-generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer (NSCLC).

                            Brand Name : TAS6417

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2022

                            Lead Product(s) : CLN-081

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Cullinan Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLN-081

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Cullinan Therapeutics

                            Deal Size : $405.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commerciali...

                            Details : Under the agreement, Taiho will acquire Cullinan Oncology’s subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan* to CLN-081/TAS6417, EGFR exon20 non-small cell lung cancer (NSCLC) regulatory milestones.

                            Brand Name : TAS6417

                            Molecule Type : Small molecule

                            Upfront Cash : $275.0 million

                            May 12, 2022

                            Lead Product(s) : CLN-081

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Cullinan Therapeutics

                            Deal Size : $405.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosnetupitant Chloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusi...

                            Details : The approval is based on results of a Phase III clinical study (CONSOLE6) comparing the efficacy and safety of Arokaris® versus fosaprepitant in patients receiving highly emetogenic chemotherapy in combination with palonosetron and dexamethasone.

                            Brand Name : Arokaris

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 28, 2022

                            Lead Product(s) : Fosnetupitant Chloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth